LyGenesis has launched an innovative experimental treatment that has the potential to change the face of medical care by growing miniature plants inside patients’ lymph nodes.
The experimental treatment, called LYG-LIV-001, involves transplanting hepatocytes, which are special liver cells obtained from a donor, into the patient’s lymph nodes.
The hypothesis behind this treatment is that these transplanted liver cells multiply and grow over time, eventually becoming fully functional liver tissue in the patient’s body.
The main goal of this innovative treatment is to offer new and effective treatment options for people suffering from end-stage liver disease (ESLD).
ESLD is a serious and often life-threatening condition that affects millions of people worldwide each year.
The lack of suitable liver donors leads to long waiting lists for liver transplants and a critical need for alternative therapies.
Although the results of ongoing clinical trials remain uncertain, LyGenesis sees a broad opportunity for this groundbreaking technology beyond treating liver disease.
If successful, it can bring new hope for patients suffering from various organ-related conditions and cause a revolution in the field of regeneration.
In March, a pilot trial began inoculating 12 patients with liver disease.
Dr. Michael Hufford, founder and CEO of LyGenesis, is optimistic about the potential of this groundbreaking treatment.
He said: “If our study is successful and we receive FDA approval, allogeneic stem cell therapy may offer the potential to treat many ESLD patients with donated livers.
This can help donors in need to resolve the current disparity between the demand and supply of organ donors. “
Liver disease is a common health problem, with millions of people diagnosed and more than 50,000 deaths worldwide each year.
Currently, around 10,000 people are on the waiting list for a liver transplant, and the availability of suitable donors is limited.
The main advantage of LyGenesis’ new treatment is that it only requires a small number of liver cells from a single donor.
This means that each liver donated can provide enough material to treat 75 patients.
This innovative approach could dramatically increase the number of people who can benefit from a single donor organ and make a huge difference in the lives of those waiting for a life-saving liver transplant.
Doctors run first human trial of growing new liver in patient’s body
